Data Sheet (Cat.No.T37082)

HS271

Chemical Properties



CAS No. : 2410393-15-4

Formula: C21H24F3N5O2

Molecular Weight: 435.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	HS271 is a selective, highly potent and orally active IRAK4 inhibitor (IC50= 7.2 μM). HS271 shows excellent enzymatic and cellular activities, as well as excellent pharmacokinetic properties.
Targets(IC50)	IRAK
In vivo	In rat models of LPS-induced TNFα production collagen-induced arthritis, HS271 (15-150 mg/kg) shows robust antiinflammatory efficacy with a t1/2 of 3.3 h and Cmax of 2107 ng/mL. The oral bioavailability of HS271 is 67.3%, 58.2%, 14.4&% and 49% in mice, rats, dogs, and monkeys, respectively[1].

Solubility Information

Solubility	DMSO: 90 mg/mL (206.69 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.58 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2965 mL	11.4826 mL	22.9653 mL
5 mM	0.4593 mL	2.2965 mL	4.5931 mL
10 mM	0.2297 mL	1.1483 mL	2.2965 mL
50 mM	0.0459 mL	0.2297 mL	0.4593 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wenqiang Zhai, et al. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors. Bioorg Med Chem Lett. 2020 Nov 24;31:127686.